Eupalinolide B |
Catalog No.GC38608
One-Click Copy Product Info
|
Eupalinolide B is a germacrane sesquiterpene lactone isolated from Eupatorium lindleyanum that possesses a variety of biological activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 877822-41-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Eupalinolide B is a germacrane sesquiterpene lactone isolated from Eupatorium lindleyanum that possesses a variety of biological activities[1-2]. Eupalinolide B induces cell apoptosis and autophagy. Eupalinolide B can be used in research related to various cancers, neurodegenerative diseases, and other conditions[3-4].
In vitro, Eupalinolide B was used to treat human hepatoma cell lines SMMC-7721 and HCCLM3 (6, 12, 24μM) for 48 hours. Eupalinolide B significantly inhibited cell proliferation by arresting the cell cycle in the S phase and induced ferroptosis mediated by endoplasmic reticulum stress and HO-1 activation[5]. Eupalinolide B (4–8μM) was used to treat RAW264.7 cells stimulated with Pg-LPS (10μg/mL) for 24 hours. Eupalinolide B significantly inhibited the expression and secretion of pro-inflammatory factors (TNF-α, IL-6, IL-1β) and suppressed IκBα phosphorylation and the activation/nuclear translocation of NF-κB p65[6].
In vivo, Eupalinolide B (20mg/kg or 40mg/kg) was administered daily via intraperitoneal injection to nude mice bearing PANC-1 pancreatic cancer cell xenografts for 4 weeks. Eupalinolide B significantly slowed tumor growth, resulting in markedly reduced tumor volume and weight[7]. Eupalinolide B (20mg/kg) was administered daily via intraperitoneal injection to a BALB/c nude mouse xenograft model bearing KRAS-mutant H358 cells for 18 days. Eupalinolide B significantly inhibited tumor growth, leading to a clear reduction in both tumor volume and weight[8].
References:
[1] Gu SL, Liu XS, Xu ZS, et al. Eupalinolide B alleviates rheumatoid arthritis through the promotion of apoptosis and autophagy via regulating the AMPK/mTOR/ULK-1 signaling axis. Int Immunopharmacol. 2025 Feb 20;148:114179.
[2] Yang L, Chen H, Hu Q, et al. Eupalinolide B attenuates lipopolysaccharide-induced acute lung injury through inhibition of NF-κB and MAPKs signaling by targeting TAK1 protein. Int Immunopharmacol. 2022 Oct;111:109148.
[3] Wang TT, Zhou MY, Gong XN, et al. Eupalinolide B alleviates corticosterone-induced PC12 cell injury and improves depression-like behaviors in CUMS rats by regulating the GSK-3β/β-catenin pathway. Biochem Pharmacol. 2025 May;235:116831.
[4] Bai Q, Wang C, Ding N, et al. Eupalinolide B targets DEK and PANoptosis through E3 ubiquitin ligases RNF149 and RNF170 to negatively regulate asthma. Phytomedicine. 2025 Jun;141:156657.
[5] Zhang Y, Zhang H, Mu J, et al. Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway. Acta Biochim Biophys Sin (Shanghai). 2022 Jul 25;54(7):974-986.
[6] Kuang W, Zhuge R, Song P, et al. Eupalinolide B inhibits periodontitis development by targeting ubiquitin conjugating enzyme UBE2D3. MedComm (2020). 2025 Jan 14;6(1):e70034.
[7] Huang Q, Yang J, Zhang J, et al. Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. iScience. 2024 Jul 14;27(8):110496.
[8] Wang W, Yu J, Huang T, et al. Eupalinolide B exerts cytotoxic effects against KRAS-mutant NSCLC through Nrf2/HO-1-regulated ferroptosis. Acta Biochim Biophys Sin (Shanghai). 2025 Dec 4.
| Cell experiment [1]: | |
Cell lines | RAW264.7 murine macrophage cell line |
Preparation Method | RAW264.7 cells were stimulated with Porphyromonas gingivalis-lipopolysaccharide (Pg-LPS) (10μg/mL) and then treated with Eupalinolide B (4–8μM). |
Reaction Conditions | 4–8μM; 24h. |
Applications | Eupalinolide B (4–8μM) significantly inhibited the expression and secretion of pro-inflammatory factors (TNF-α, IL-6, IL-1β), and suppressed IκBα phosphorylation and NF-κB p65 activation/nuclear translocation in Pg-LPS-stimulated RAW264.7 cells. |
| Animal experiment [2]: | |
Animal models | BALB/c nude mice bearing KRAS-mutant H358 cell xenograft tumors |
Preparation Method | Mice were subcutaneously injected with H358 cells (5×10⁶) in serum-free medium into the right dorsum. The experimental group was then treated with Eupalinolide B (20mg/kg) via daily intraperitoneal injection for 18 days. Tumor volume and body weight were monitored. |
Dosage form | 20mg/kg; i.p.; once daily for 18 days. |
Applications | Eupalinolide B administration significantly inhibited tumor growth, resulting in reduced tumor volume and weight. Histopathological (H&E) analysis confirmed that Eupalinolide B markedly induced tumor cell damage. Eupalinolide B treatment increased the protein levels of Nrf2, HO-1, and ACSL4, while decreasing the levels of Keap1, GPX4, and FTH1 in tumor tissues, indicating the induction of ferroptosis in vivo. |
References: | |
| Cas No. | 877822-41-8 | SDF | |
| Canonical SMILES | O=C(O[C@@H]1C/C(COC(C)=O)=C/C[C@H](OC(C)=O)/C(C)=C/[C@@]([C@]1([H])C2=C)([H])OC2=O)/C(C)=C/CO | ||
| Formula | C24H30O9 | M.Wt | 462.49 |
| Solubility | Soluble in DMSO | Storage | -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1622 mL | 10.811 mL | 21.6221 mL |
| 5 mM | 432.4 μL | 2.1622 mL | 4.3244 mL |
| 10 mM | 216.2 μL | 1.0811 mL | 2.1622 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)